ReviewJournal of the Chinese Medical Association : JCMA2021
Blood pressure management and renal protection: Revisiting hypertensive nephropathy.
Review in Journal of the Chinese Medical Association : JCMA, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Salvianolate injection for hypertensive nephropathy patients who were using valsartan: A systematic review and meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Associations of insulin resistance-related metabolic indices with albuminuria in primary hypertension without diabetes: a retrospective cross-sectional study.Frontiers in medicine · 2026Article
- Trends, Social Determinants, and Lifestyle Factors Associated With Comorbidity of Diabetes and Kidney Diseases Among Chinese Adults Aged ≥ 45 Years.Journal of diabetes · 2025Observational
- Renoprotective and antihypertensive mechanism of action of Clinacanthus nutans bioactive polysaccharides by suppression of reactive oxygen species/ nuclear factor/ matrix metalloproteinase (ROS/NF-ΚB/MMP-9) and upregulation of endothelial nitric oxide synthase/nitric oxide (eNOS/NO) pathways.Journal of molecular histology · 2025Article
- Article
- Association of Systemic Inflammatory Biomarkers (NLR, MLR, PLR, SII, SIRI) with Preeclampsia-Related Kidney Injury: A Retrospective Observational Study.Journal of inflammation research · 2025Article
- Renal effects of selective cyclooxygenase-2 inhibitor anti-inflammatory drugs: A systematic review and meta-analysis.Exploratory research in clinical and social pharmacy · 2024Review
- Cumulative blood pressure load and hypertensive nephropathy in Han Chinese hypertensive patients.Journal of clinical hypertension (Greenwich, Conn.) · 2024Article
- Targeting the epidermal growth factor receptor (EGFR/ErbB) for the potential treatment of renal pathologies.Frontiers in pharmacology · 2024Review
- Flavonoids in Treatment of Chronic Kidney Disease.Molecules (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension has traditionally been the most common cardiovascular disease, and epidemiological studies suggest that the incidence continues to rise. Despite a plethora of antihypertensive agents, the management of blood pressure (BP) remains suboptimal. Addressing this issue is paramount to minimize hypertensive complications, including hypertensive nephropathy, a clinical entity whose definition has been challenged recently. Still, accumulating studies endorse poorly managed BP as an independent risk factor for both the onset of renal dysfunction and aggravation of baseline kidney disease. Nevertheless, current recommendations are not only discordant from one another but also offer inadequate evidence for the optimal BP control targets for renal protection, as since the cutoff values were primarily established on the premise of minimizing cardiovascular sequelae rather than kidney dysfunction. Although intense BP management was traditionally considered to compromise perfusion toward renal parenchyma, literature has gradually established that renal prognosis is more favorable as compared with the standard threshold. This review aims to elucidate the renal impact of poorly controlled hypertension, elaborate on contemporary clinical references for BP control, and propose future directions to improve the holistic care of hypertensive individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.